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Abstract
Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. A number of molecular
profiling studies have investigated the changes in gene and protein expression that are associated with various
clinicopathological characteristics of HCC and generated a wealth of scattered information, usually in the form of
gene signature tables. A database of the published HCC gene signatures would be useful to liver cancer
researchers seeking to retrieve existing differential expression information on a candidate gene and to make
comparisons between signatures for prioritization of common genes. A challenge in constructing such database is
that a direct import of the signatures as appeared in articles would lead to a loss or ambiguity of their context
information that is essential for a correct biological interpretation of a gene’s expression change. This challenge
arises because designation of compared sample groups is most often abbreviated, ad hoc, or even missing from
published signature tables. Without manual curation, the context information becomes lost, leading to
uninformative database contents. Although several databases of gene signatures are available, none of them
contains informative form of signatures nor shows comprehensive coverage on liver cancer. Thus we constructed
Liverome, a curated database of liver cancer-related gene signatures with self-contained context information.
Description: Liverome’s data coverage is more than three times larger than any other signature database,
consisting of 143 signatures taken from 98 HCC studies, mostly microarray and proteome, and involving 6,927
genes. The signatures were post-processed into an informative and uniform representation and annotated with an
itemized summary so that all context information is unambiguously self-contained within the database. The
signatures were further informatively named and meaningfully organized according to ten functional categories for
guided browsing. Its web interface enables a straightforward retrieval of known differential expression information
on a query gene and a comparison of signatures to prioritize common genes. The utility of Liverome-collected
data is shown by case studies in which useful biological insights on HCC are produced.
Conclusion: Liverome database provides a comprehensive collection of well-curated HCC gene signatures and
straightforward interfaces for gene search and signature comparison as well. Liverome is available at http://
liverome.kobic.re.kr.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon and the third most deadly cancer worldwide,
accounting for 600,000 deaths annually [1]. Clinical
observations have established that most HCC patients
have underlying chronic liver diseases; 70-80% of HCC
patients suffer from liver cirrhosis caused by chronic
infection of hepatitis B virus or hepatitis C virus, exces-
sive alcohol consumption, or certain metabolic disor-
ders. In addition, male gender and exposure to
environmental toxins such as aflatoxin increase the risk
of developing HCC. Further, recent genetic and genomic
studies have pointed to germline or somatic DNA
alterations and specific molecular pathways for the
initiation and progression of HCC. Currently, only one
third of newly diagnosed HCC patients are eligible for
potential curative therapies, mainly due to a lack of
early detection technology and limited choices of effec-
tive therapeutic agents [2]. Early accurate diagnosis and
effective treatment of HCC require a deep understand-
ing of how it occurs at a molecular and cellular level.
Advances in high-throughput technologies in tran-
scriptomics and proteomics have changed the way in
which HCC is studied and, potentially, diagnosed and
classified in clinical practice. During the last decade, a
number of molecular profiling studies have investigated
changes in gene and protein expression that are induced
by HCC. While early studies had focused on the com-
parison of expression profiles between tumorous and
non-tumorous liver, later studies have more fully
explored the molecular pathogenesis of HCC by asso-
ciating expression changes with various clinicopathologi-
cal characteristics of HCC such as etiology, prognosis,
metastasis, and HCC subgroups.
The result from the molecular profiling studies most
often comes in the form of a list of genes, also called a
gene signature, which is reported in research articles as
a table in the main text or a supplementary table. The
gene signature typically consists of gene identifiers and
numerical ranking information such as fold change, p-
value, and other relevant statistics that describe the nat-
ure and the strength of association between the gene
and the phenotype under study. Each of the gene signa-
tures derived from profiling studies on HCC gives a dis-
tinct molecular portrait of a specific aspect of HCC
under a specific sample cohort. Collective information
that arises from a wealth of diverse gene signatures is
expected to contribute significantly to a comprehensive
understanding of molecular events underlying HCC and
to the prioritization of candidate target genes for diag-
nosis and treatment.
Specifically, the collection of published gene signatures
can be useful to liver cancer researchers in two most
common situations. In one situation, a researcher may
hypothesize that a particular gene is implicated in HCC
and seek published evidences supporting the hypothesis.
For this purpose, the candidate gene can be searched on
the gene signature collection to retrieve all available dif-
ferential expression evidences. If the search shows com-
pelling evidences, the candidate gene can be further
examined in depth by experimental means. In the other
situation, a researcher might have performed a molecu-
lar profiling study to derive a gene signature associated
with a particular phenotype under the study, for exam-
ple, survival of HCC patients. Then, the derived signa-
ture can be compared with survival-associated
signatures in the collection to identify common genes.
Such common genes can be considered as robust mar-
ker genes that are reproducible across independent sam-
ple cohorts, and their identification can help prioritize
the user-derived signature for a further in-depth valida-
tion study. To effectively serve as the gene search and
signature comparison resource for liver cancer research
community, we argue that a gene signature database
needs to be constructed with the following considera-
tions on web interface and database content, all of
which have not been addressed by other gene signature
databases currently available, such as CCancer [3],
dbDEPC [4], EHCO [5], and GeneSigDB [6].
With respect to the web interface, the first aspect to
consider is that the gene signature collection should be
linked to both a gene search interface that retrieves dif-
ferential expression information of query gene as well as
a signature comparison interface that compares user-
selected signatures to identify common genes for priori-
tization. Second, to facilitate signature comparison, the
collected signatures need to be meaningfully organized
for guided browsing according to their functional cate-
gory, such as etiology, survival, recurrence, and differen-
tiation. Third, it should be beneficial to give each
signature an informative name for a quick recognition
and easy browsing. Due to the diversity of HCC gene
signatures, a cluttered collection without the meaningful
organization and the informative naming would make it
difficult to browse through the voluminous gene signa-
ture collection.
With respect to the database content, the first aspect
to consider is that the gene signature collection should
be comprehensive and up-to-date, covering most, if not
all, published HCC gene signatures that associate
expression changes with various characteristics of HCC.
Second aspect worth considering is to present numerical
ranking value in a uniform representation. Published
gene signature tables present fold change values in var-
ious formats, such as ratio, log ratio, fold change with a
direction tag, and a pair of intensity values. Presenting
them in a uniform format will make it more intuitive to
recognize similar data and make comparisons across
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signatures. Third, and most importantly, context infor-
mation of gene signatures needs to be curated to the
extent that all information is unambiguously self-con-
tained within the database. With the availability of self-
contained context information, database users would
not have to refer to source articles from which the sig-
natures were reported. The context information of a
gene signature comes in two types: (i) summary of
experiment that produced the gene signature, and (ii)
explicit designation of compared sample groups asso-
ciated with numerical ranking value (for example, fold
change in poorly-differentiated samples compared to
well-differentiated samples). The summary of experi-
ment would be helpful for database users to quickly
recognize detailed characteristics of gene signatures and
it should document platform, clinicopathological sample
characteristics, sample size, data analysis method, and
others. More crucial piece of information is the explicit
designation of compared sample groups associated with
numerical ranking value, which is utmost essential for a
correct biological interpretation of a gene’s expression
change.
Nevertheless, the explicit designation of compared
sample groups is most often ignored by other gene sig-
nature databases since it can only be prepared through
additional manual curation effort. In most gene signa-
ture tables appeared in research articles, sample group
names are either abbreviated, ad hoc, or even missing
from the table column title. Instead, the sample groups
are usually designated in full in the source article’s table
legend or main text. The abbreviated, ad hoc, or missing
table column title poses no problem with respect to the
article itself, but becomes problematic upon incorporat-
ing into database. Since other gene signature databases
merely extract gene signatures as they appear in the
published tables without further manual curation, the
sample group designation becomes ambiguous or even
lost from the collected gene signatures, leading to an
uninformative form of gene signatures. In Figure 1, we
show examples of published gene signature tables, unin-
formative form of gene signatures collected in other
databases, and informative form of gene signatures that
we derived through manual curation. A database con-
taining the uninformative gene signatures would merely
produce a meaningless search result, as illustrated later
in the “Comparison to other resources” section. While it
would not be impossible for database users to obtain
the information on sample group designation from
source articles, doing so would be very inconvenient
and greatly undermine the practical utility of the
database.
To address all these unmet needs toward a straightfor-
ward gene search and signature comparison resource for
liver cancer research community, we constructed
Liverome, a curated database of liver cancer-related
gene signatures with self-contained context information.
Here, the self-contained context information includes
both the summary of experiment that produced the sig-
nature and the explicit designation of compared sample
groups associated with numerical ranking value. Its col-
lection consists of 143 signatures compiled from 98
HCC-related profiling studies, mostly microarray and
proteomics, and involves 6,927 genes. The size of our
HCC signature collection is more than three times lar-
ger than any other signature database (Figure 2). The
collection was manually post-processed, annotated, and
systematically organized in order to provide informative
and self-contained database contents. The database can
be accessed through two web interfaces: (i) a gene
search interface that retrieves self-contained differential
expression information on query gene, consisting of
numerical ranking value in uniform representation,
explicit designation of compared sample groups, and
summary of experiment, and (ii) a gene signature com-
parison interface that facilitates guided browsing of sig-
nature collection and comparison of user-selected
signatures to identify common genes, ordered by occur-
rence frequency. The uniqueness of Liverome in terms
of database size, database content, and web interface,
are summarized later in the “Comparison to other
resources” section. Liverome is most useful to retrieve
well-curated supporting evidences from published mole-
cular profiling studies in HCC on a user-specified candi-
date gene or gene signature. In profiling studies, authors
usually select a handful of genes for validation or discus-
sion in the article without paying much attention to the
rest of the genes in their signature. With Liverome,
underused information that is buried within the pre-
viously reported HCC gene signatures can be brought
back to the surface. Liverome is available at http://liver-
ome.kobic.re.kr.
Construction and content
Collecting and extracting gene signatures
We collected 98 HCC-related profiling studies, consist-
ing of 83 transcriptomic studies, 12 proteomic studies,
and three other genome scale studies. We collected only
those articles that met our collection criteria; (i) articles
should report novel experimental findings (that is, we
excluded review articles), (ii) the experiment should be
done on HCC patients or human HCC cell lines (that is,
we excluded studies done on mouse models), and (iii)
the article should report gene signature tables contain-
ing enough genes (which was set arbitrarily to eight or
more genes). From the main text and supplementary
material of collected articles, we manually extracted
gene signatures that are reported as tables (or as heat-
map figures in a few cases), totalling 143 gene signatures
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listed in Table S1 (Additional File 1). Statistics of the
gene signatures are further summarized in Table S2
(Additional File 1) with respect to ten functional cate-
gories: (1) tumor versus non-tumorous liver comparison,
(2) survival/recurrence, (3) cirrhosis/dysplasia, (4) etiol-
ogy, (5) differentiation, (6) invasion/metastasis, (7) geno-
mic alterations, (8) modulation by a gene/protein factor,
(9) HCC subgroups, and (10) other nature.
Post-processing the extracted signatures into uniformly
formatted, informative, and self-contained form
Once the gene signature tables were extracted, we
manually post-processed them to convert into a uni-
formly formatted, informative, and self-contained form.
The conversion was made under the following four
guiding principles. First, fold change values are pre-
sented in non-logarithmic ratio and non-ratio scale
Figure 1 Examples on how gene signatures appear in articles, in other databases, and in Liverome. The left, middle, and right columns
show gene signatures as appeared in articles, in other gene signature databases, and in Liverome, respectively. Column titles for numerical
ranking information were abbreviated or ad hoc in the original gene signature tables (left column). Gene signatures extracted by other databases
are uninformative (middle column): (A) direct import of original table causes an ambiguity as to what P1 and P2 means and to the context of
the observed expression changes (Down and Up), (B) importing only the gene identifiers causes a complete loss of differential expression
information, and (C) importing only the change direction causes a loss of numerical information as well as an ambiguity as to the context of the
observed expression changes. Shown in blue highlights how the information from the original signature tables became transformed in the
databases. Liverome derives the most informative form of gene signatures through manual curation to construct self-contained database
content (right column). In addition, for an easier recognition, fold change values were uniformly formatted (shown in red) and signatures were
informatively named (shown in green) in Liverome.
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along with a direction tag. For example, “7.000 Down”
was uniformly used to represent the reported equivalent
values such as a ratio value of 0.1428, a log2 ratio value
of -2.8073, a text value of ↓7.0, or a pair of intensity
values of 50 and 350. Second, the column titles for fold
change should explicitly designate case and control sam-
ple groups, such as tumor/normal, poor survival group/
good survival group, and invasive tumor/non-invasive
tumor, in which the case group is designated in the
numerator and the control group in the denominator.
Third, columns that give inessential information, such
as the confidence interval of a test statistic, may be
omitted for a succinct representation, or columns that
do not exist in the original tables may be added when
necessary; an example being a direction tag (up or
down). Fourth, a gene signature table may be split into
several signatures or several tables may be combined
into one signature when appropriate. All the published
gene signature tables needed to be post-processed to
some extent, and attention to detail was paid through-
out the post-processing to give the most informative
database content, which was made possible only after
first reading and understanding the source articles. The
post-processing of gene signatures is a unique feature of
Liverome’s database content.
In addition to the numerical ranking information,
gene or protein identifiers were extracted and mapped
to the most recent EntrezGene IDs using mapping files
obtained from NCBI. In the absence of definite identi-
fiers, for example when only the gene names were pro-
vided in the published signature tables, corresponding
gene identifiers were acquired manually. We excluded
entries that cannot be reliably mapped to EntrezGene,
such as ambiguous gene names or retired UniGene IDs
without further traceable information.
Annotating gene signatures: informative naming and self-
contained documenting
Subsequent to the post-processing of the extracted signa-
tures, we further annotated them to produce informative
signature name and itemized summary. The annotation
effort was made in order to help database users recognize
the nature of gene signatures without having to read the
source articles. First, since an ad hoc naming of gene sig-
natures (for example, “Viral_Okamoto06_36genes” shown
in the middle of Figure 1A) would significantly hinder the
Figure 2 Comparison of HCC data coverage between Liverome and four other signature databases. For each of the databases, the
number of collected HCC-related articles from which gene signatures were extracted is indicated. The four other databases show minimal
overlaps with each other. Liverome’s collection is more than three times larger than any other database. One third of its data (thirty articles) is
unique to Liverome. Only the articles that met our collection criteria were counted, as described in the “Construction and content” section.
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quick recognition, we gave each gene signature an infor-
mative name of the form “Author (Year) Journal [Short
name]” (for example, “Okamoto (2006) Ann Surg Oncol
[Predictive marker genes for multicentric hepatocarcino-
genesis]” shown in the right of Figure 1A). For gene signa-
tures obtained from a two-class comparison, the short
name generally takes the form of “case vs. control”, such
as recurrence group vs. recurrence-free group, tumor vs.
non-tumor, and tumor vs. normal liver. As shown in the
latter two examples, we made a distinction between non-
tumor (adjacent non-tumorous normal tissue) and normal
liver (normal tissue from a tumor-free subject) since the
two types of control samples have different characteristics
[7]. For gene signatures obtained from other types of ana-
lyses, either the names used in the source articles or the
names that we appropriately designated were used. Sec-
ond, for each gene signature, we read its source article and
prepared a detailed yet concise itemized summary docu-
menting basic nature of the signature, platform, signature
length, sample size, clinicopathological sample characteris-
tics, data analysis method, and reference information. The
gene signature summary page appears as a pop-up window
upon clicking on the name of the gene signature through-
out the web site (Figure 3A). The annotation of gene sig-
natures is also a unique feature of Liverome’s data content.
Utility and discussion
Web interface
Liverome database is implemented in MySQL, and its
web interface is written in PHP and JavaScript under
Apache web server running on a Linux system. Liver-
ome provides two types of interface: (i) search interface
for a gene, and (ii) browse and comparison interface for
gene signatures. The result from the gene search inter-
face is the informatively named gene signature hits in
which the queried gene is found, along with numerical
ranking information in uniform representation and
explicit designation of compared sample groups (Figure
3B). On the browse and comparison interface, gene sig-
natures are organized for guided browsing into ten
groups according to their functional categories (Figure
3C). This interface is to be used when one or more col-
lected signatures need to be retrieved and compared, or
when users want to compare their signature with col-
lected ones. In all cases, users need to select the desired
signatures by marking their checkboxes. Comparing a
user-provided signature with all the collected signatures
is equivalent to performing a batch query.
The selected signatures are then passed to the next
screen in which a combined gene signature table
appears (Figure 3D), along with three additional menus
in the left: export data, pathway grouping, and GO
(Gene Ontology) grouping. The grouping is a simple
version of enrichment analysis, in which all the present
KEGG pathway or GO terms are reported without
applying a p-value cutoff. For an advanced enrichment
analysis, users can export the accessed gene signature to
an Excel file for the use of a third party tool. Several
display controls are also provided above the gene signa-
ture table, such as the one that allows viewing the num-
ber of pairwise overlapping genes between signatures
[6,8]. The most important control is “sorted by”. The
order of genes in the table can be sorted by multiple
columns in a sequential manner (that is, a spreadsheet-
like sorting) by clicking the upward or downward arrows
in the header row; the “sorted by” field shows the sort-
ing sequence. The default ordering is set in a way that
is the most reasonable under the given context, such as
a descending sort on occurrence frequency followed by
a sort on the gene symbol when multiple signatures are
retrieved. The default ordering can be cleared by click-
ing “undo all sorting” and re-ordered by users. The sort-
ing functionality should be useful to sort out the genes
that are supported by multiple evidences or a particular
set of evidence. An exercise on sorting is shown in the
user guide on the web site.
Comparison to other resources
There are several recently constructed databases that
provide an access to published signatures. One is speci-
fic to HCC (EHCO [5]), thus the most directly compar-
able to Liverome, while the other three are broadly
scoped encompassing all types of cancer (dbDEPC [4])
and some additional phenotypes as well (CCancer [3]
and GeneSigDB [6]). Each of these resources, including
ours, is aimed at its own specific utility, serves particular
target user group, and has both strengths and limita-
tions. Thus, we compare them with respect to Liver-
ome’s main utility as a gene search and signature
comparison resource for liver cancer research commu-
nity (Table 1), while acknowledging the benefits offered
by each of the resources as well.
With respect to data coverage, Liverome’s collection of
143 HCC-related signatures from 98 articles represents
a data coverage of more than four times larger (signa-
ture-wisely) and three times larger (article-wisely) than
any other resource. As seen in the Venn diagram of Fig-
ure 2, two thirds of Liverome’s collection (68 articles)
represents a consolidated data coverage of all other
resources while one third (30 articles) is unique to
Liverome. Despite the broad scope and overall large
coverage attained in CCancer and GeneSigDB, their
HCC-specific coverage is merely less than one quarter
of Liverome, which points to the need of a gene signa-
ture database dedicated to HCC.
With respect to data content, the benefits offered by
Liverome’s manual curation are noticeable. Compared
sample groups are explicitly designated only in Liverome
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Figure 3 The web interface of Liverome. (A) Itemized summary of gene signature, which appears as a pop-up window upon clicking on the
name of the signature, as indicated by red rounded rectangles in the figure. (B) Result from gene search interface which reports the
informatively named gene signature hits in which the queried gene is found (left column), along with numerical ranking information and
designation of compared groups (right column). (C) The browse and comparison interface in which three signatures are marked. (D) Result from
the browse and comparison interface. Several display controls are provided at the top of the screen. The table below provides a sorted view of
all the genes that are found in the selected signatures. The sequence of the sorting applied to the table is shown on the right of the “Sorted
by” control. This table was made compact by using the “Set columns to display” control. See the user guide on the web site for more
information.
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and one other database (dbDEPC). Three aspects of pro-
ducing informative content are not addressed by any
other database. In particular, EHCO and CCancer did
not curate their collected data at all, lacking all five
aspects of producing informative data content. In the
absence of informative data content, a gene search on
the database would not be informative either; the search
result would merely indicate the gene signature hits in
which the query is found (Figure 4A). Thus, to go
beyond recognizing the query gene has some HCC-
related evidence, database users would need to figure
out the numerical ranking value and the context in
which the query gene is associated with HCC by reading
source articles. While doing so would not be impossible,
it would be very inconvenient and greatly undermine
the practical utility of the database. In contrast, a gene
search result on Liverome is informative; all information
retrieved from the gene search is readily readable and
self-contained in one screen (Figure 4B).
With respect to web interface, features unique to
Liverome are functional categorization of gene
signatures for guided browsing and spreadsheet-like
sorting utility for occurrence-based prioritization. Liver-
ome also has a distinctive implementation for signature
comparison and gene search interfaces, which are differ-
ent from corresponding interfaces implemented in other
resources. The signature comparison interface of Liver-
ome allows users to select a subset of comparable signa-
tures of similar nature (for example, survival-associated
gene signatures), whereas those of other resources do
not. The gene search interface of Liverome is designed
to produce a search result screen in which all informa-
tion is readily readable and self-contained in one screen
(Figure 4B). Obtaining such information from other
resources requires reading the source articles and/or fol-
lowing multiple hyperlinks.
Although Liverome is superior to other resources with
respect to its own utility as a gene search and signature
comparison tool for liver cancer research community,
the other resources also offer benefits not addressed by
Liverome. CCancer enables identification of frequently
co-reported gene pairs, computes signature overlap
Table 1 Comparison of Liverome with other related tools
Liverome EHCO dbDEPC CCancer GeneSigDB
Data coverage
Coverage of phenotype HCC only HCC only 15 cancers Half the data are on
cancer
Mostly cancer and
stem cell
Coverage of HCC-specific data (signatures
// articles)
143 // 98 12 // 32 6 // 5 25 // 21 34 // 18
Overall data coverage Same as above Same as above 65 // 48 3369 // 2644 2142 // 973
Covers both transcriptomics and
proteomics studies
Yes Yes No (proteomics
only)
Yes Yes
Data content
Explicit designation of compared sample
groups
Yes No Yes No No
Contains numerical ranking information Yes No (change
direction only)
Yes (fold
change only)
No Yes
Uniform representation of numerical
ranking values
Yes (unique to
Liverome)
No No No No
Informative naming of signatures Yes (unique to
Liverome)
No No No No
Summary of experiment Yes (unique to
Liverome)
No No No No
Web interface
Signature comparison tool Yes No Yes Yes Yes
Gene search tool Yes Yes Yes No Yes
Functional categorization of signatures for
guided browsing
Yes (unique to
Liverome)
No No No No
Spreadsheet-like sorting utility for
prioritization
Yes (unique to
Liverome)
No No No No
Liverome is compared to four other gene signature databases with respect to Liverome’s main utility as a gene search and signature comparison resource for
liver cancer research community. Liverome achieves the largest coverage of HCC signatures and the most informative data content at the same time. Its web
interface is designed to facilitate the retrieval of the informative data content, the guided browsing of signatures, and their comparison for occurrence-based
prioritization.
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p-values, and provides by far the largest overall data
coverage achieved through an automatic extraction of
gene identifiers at the expense of missing numerical
ranking information. GeneSigDB computes signature
overlap p-values, maintains a trace of identifier mapping
between the original and the re-mapped signatures, and
provides a large overall data coverage even with acquisi-
tion of both gene identifiers and accompanying
numerical ranking information. dbDEPC provides an
explicit designation of the compared sample groups and
the largest coverage of cancer-related protein signatures.
All three generic resources can be a useful tool for glo-
bal cross-comparison of heterogeneous cancer types. As
for EHCO, the most directly comparable HCC-specific
resource, we did not find any major comparative bene-
fits that it offers. It does provide, however, a list of
Figure 4 A gene search result is informative only in the presence of informative data content. (A) A search for IGFBP3 gene on EHCO
database produces an uninformative result. To decipher the retrieved result, users need to read the source article named “mRNA” to figure out
whether the observed expression change of the gene was up-regulation or down-regulation under that dataset as well as the compared sample
groups. (B) A search for IGFBP3 gene on Liverome produces an informative result; all information is readily readable and self-contained in one
screen.
Lee et al. BMC Genomics 2011, 12(Suppl 3):S3
http://www.biomedcentral.com/1471-2164/12/S3/S3
Page 9 of 13
HCC-related genes derived through text mining, which
was imported to our database as one of the collected
signatures. In addition, they reported in the article an
interesting post-construction analysis of protein-protein
interaction network using EHCO-collected data.
To summarize, our collection of HCC-related gene
signatures is the most comprehensive. Furthermore, we
generated the most informative and self-contained data-
base contents through manual post-processing and
annotation, which had not been done in other databases.
Our web interfaces are the most straightforward for the
retrieval of well-curated differential expression informa-
tion on a query gene, the guided browsing of signature
collection, and the comparison of signatures for occur-
rence-based prioritization of common genes. In the
future, we will continuously expand Liverome’s signa-
ture collection once a year by incorporating newly pub-
lished HCC gene signatures. Next we demonstrate the
utility of Liverome by presenting several examples in
which useful biological insights on HCC are produced.
Case study 1: genes that are frequently reported among
the gene signature collection in Liverome
With a database like Liverome, one natural question
that can be raised is which genes are most frequently
reported among the various collected gene signatures.
To answer this question, we marked all 143 gene signa-
tures from the browse and comparison interface and
sorted the genes by occurrence frequency. Out of all
6,927 genes, about half of them occur in only one signa-
ture while a few genes occur frequently (Figure S1,
Additional File 2). Top 22 most frequent genes occur-
ring in 12 or more signatures are listed in Table S3
(Additional File 1).
Glypican 3 (GPC3) was identified as the third most
frequently reported gene, observed in 17 gene signa-
tures. GPC3 is a heparan sulfate proteoglycan that is
attached to the cell surface by a glycosylphosphatidyli-
nositol anchor. Previous studies have pointed to its con-
nection to HCC. GPC3 is highly expressed in HCC [9],
stimulates the growth of HCC cells in vitro and in vivo
by activating the canonical Wnt signaling [9], and mod-
ulates cell proliferation through fibroblast growth factor
2 and bone morphogenetic protein 7 signaling [10]. To
confirm that the reported up-regulation of GPC3 in
HCC is a frequent event and is captured by microarray
studies across various platforms, we searched for GPC3
in Liverome. From the 17 gene signature hits that con-
tain GPC3, we could easily confirm that the up-regula-
tion of GPC3 is consistently supported by eight
signatures derived from comparison of tumor with non-
tumor or normal liver, along with large fold change
values (Figure S2, Additional File 2). This collective
information further supports the previously suggested
usefulness of GPC3 as a potential diagnostic marker for
HCC and a target for antibody-based therapeutic inter-
vention of HCC [11].
In addition, two genes that encode enzymes in the
one-carbon metabolism pathway, namely betaine-homo-
cysteine S-methyltransferase (BHMT) and methylenete-
trahydrofolate dehydrogenase 1 (MTHFD1), were
identified as the fourth and seventh most frequently
reported genes, observed in 16 and 13 signatures,
respectively. It is known that epigenetic alterations, such
as global hypomethylation, regional hypermethylation of
tumor suppressor genes, and histone modification that
alters chromatin structure, are involved in HCC. One-
carbon metabolism, with S-adenosylmethionine (SAM)
as the principal biological methyl donor, is required for
the epigenetic events. Both BHMT and MTHFD1 are
involved in the synthesis and regulation of SAM. Several
lines of evidence have suggested that one-carbon meta-
bolism plays an important role in HCC. First, folate/
methyl-deficient rat models have shown that sufficient
supply of SAM can prevent HCC development whereas
chronic depletion of SAM can lead to HCC [12]. These
models also reported an altered expression of epigenetic
enzymes such as DNA methyltransferases (DNMTs) and
methyl CpG binding proteins (MBDs) [13]. The aberrant
regulation of DNMTs and MBDs have been observed in
HCC patients and are suggested to be involved in silen-
cing of tumor suppressor genes leading to uncontrolled
cell growth and activation of metastasis genes, respec-
tively [14]. Second, it was reported that administration
of SAM in rats reduced the expression of c-myc, Hras,
and Kras oncogenes in proliferating liver cells and
tumor nodules [15]. Third, by searching for BHMT and
MTHFD1 in Liverome, we could easily see that down-
regulation of the two genes is prevalent in proliferative
and poorly differentiated HCCs (Figures S3 and S4,
Additional File 2). These evidences might shed light on
the role of one-carbon metabolism genes in HCC pro-
gression, possibly through epigenetic regulation.
Case study 2: genes with somatic mutation in HCC
Next, we sought to retrieve supporting information on
genes with somatic mutation in HCC using Liverome.
All cancers arise from acquisition of a series of fixed
DNA sequence abnormalities, many of which ultimately
confer a growth advantage to the cells in which they
have occurred. COSMIC (Catalogue of Somatic Muta-
tions in Cancer) database [16] provides the somatic
mutation information but not the gene expression infor-
mation. In order to collect comprehensive data on genes
with somatic mutation in HCC, we first identified fre-
quently mutated genes in HCC from COSMIC with the
following three criteria: primary tumor samples only, a
minimum of 5% somatic mutation frequency, and a
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minimum of ten samples screened. There were eleven
such genes. Upon searching for those genes on Liver-
ome, differential expression information of eight of the
genes (CSF1R, CTNNB1, CDKN2A, RB1, HNF1A, KRAS,
MET, and PTEN) was retrieved (Table S4, Additional
File 1), which may provide further understanding of
these genes.
Case study 3: metabolic genes
ATP citrate lyase (ACLY) is a key lipogenic enzyme that
catalyzes the synthesis of acetyl-CoA from mitochon-
dria-derived citrate in the cytoplasm, a unique step that
links cellular glucose catabolism and lipid synthesis.
ACLY has been documented as being dramatically upre-
gulated in a number of human carcinoma cell lines with
high aerobic glycolytic activities, such as breast and
bladder carcinoma [17]. Higher glycolysis is thought to
not only provide ATP for the tumor’s high energy
demands, but also provide precursors for anabolic pro-
cesses, including de novo fatty acid synthesis that uti-
lizes acetyl-CoA as the initial precursor. In support of
the notion that increased glycolysis contributes to
enhanced carcinogenesis by providing self-produced
fatty acids for membrane biosynthesis, suppression of
ACLY through genetic and pharmacological approaches
was shown to result in a remarkable inhibition of prolif-
eration and differentiation of certain carcinoma cell
lines [18]. However, it is currently unclear whether the
dysregulated expression of ACLY contributes to the
initiation, progression, and metastasis of HCC. Interest-
ingly, ACLY is located in chromosome 17q, a frequently
amplified region in HCC tissues [19]. By searching
Liverome, we found that four gene expression studies
have reported an up-regulation of ACLY in HCC (Figure
S5, Additional File 2). Combined with the known func-
tions of ACLY in other solid tumors, the information
retrieved from Liverome suggests that ACLY can be a
potential target for HCC treatment. In addition, through
a Liverome search, we found that the glucose transpor-
ter SLC2A1 (also called GLUT1), another important
player in cancer metabolism [20], was upregulated in
AFP-positive HCC tissues and was downregulated in
AFP-negative HCC tissues (Figure S6, Additional File 2).
This piece of information raises the possibility that dif-
ferent HCC patient segments may have different GLUT1
expression level.
Case study 4: co-occurrence network analysis
Lastly, we applied a systems biology approach to study
the relationship among the genes collected in Liverome
and whether such relationship recapitulates known HCC
biology. Toward this end, we constructed a gene co-
occurrence network consisting of all 6,329 genes in the
92 gene signatures in Liverome 2010 version. Briefly,
each gene i in Liverome was associated with a binary
vector gi of length N (=92; the total number of gene
lists). Each element gij was set to 1 if the gene i belongs
to the gene list j and 0 otherwise. We then constructed
a co-occurrence network in which each node represents
a gene and each edge represents a gene pair’s similarity
as measured by the Jaccard similarity coefficient
between the two gene vectors. In other words, a pair of
genes is considered similar if the two genes occur
together in the same gene list frequently. Using the
WGCNA method [21], we then identified 38 gene mod-
ules that represent strongly inter-connected genes in the
network. More details on the network construction and
module identification can be found in Additional File 3.
The modules were then searched for enrichment of
known biological pathways in MSigDB [22]. Results
show that 24 of the 38 modules are statistically signifi-
cantly enriched in at least one curated pathway (Addi-
tional File 4). The enriched modules reveal many
interesting pathways that are relevant to cancer and
HCC in particular (Figure 5). For example, the M19 and
M5 modules are both enriched in cell cycle genes
(p<0.001 and p<0.0002 by Fisher’s exact test). The M19
module contains core cell cycle checkpoint genes such
as CCNA2, E2F2, and MCM3, whereas the M5 module
includes genes such as ANLN, PRC1, and RACGAP1,
which are mostly involved in cytokinesis. Several mod-
ules, such as the M26 module (p<0.0022), are enriched
in glycolysis pathway genes, which have recently been
shown to be critical for HCC tumor growth and therapy
failure [23,24]. Furthermore, the M1 module, which is
the largest module consisting of 1,018 genes, are
enriched for a number of important cancer-related path-
ways including immune response, angiogenesis, apopto-
sis, cell adhesion, metabolism, among others. The M1
module seems to represent the core HCC machinery
that integrates signals from both internal and external of
the tumor cell to adapt to the tumor’s needs to grow
and migrate. Most of these enriched pathways were also
observed in co-expression network modules identified
from a gene expression dataset of a large cohort of
HCC primary tumors [25]. Taken together, the co-
occurrence network analysis recapitulates known HCC
biology and demonstrates that the collective information
captured in Liverome is valuable.
Conclusions
Liverome database provides a comprehensive collection
of well-curated HCC gene signatures and straightfor-
ward interfaces for gene search and signature compari-
son as well. The collected signatures were subjected to a
thorough manual post-processing before inclusion into
the database. Deriving a uniformly formatted and infor-
mative form of gene signatures with self-contained
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context information was the key aim of the post-proces-
sing. Characteristics of the gene signatures were also
manually annotated to produce an informative signature
naming and a detailed yet concise itemized summary.
The web interface of Liverome displays gene search
result in the most readable way, organizes the diverse
gene signatures according to their functional categories
for guided browsing, and enables their comparison to
identify and prioritize common genes. Using Liverome,
liver cancer researchers can have convenient access to a
comprehensive and well-curated set of HCC gene signa-
tures accumulated from a decade of molecular profiling
studies on HCC. Liverome is most useful to retrieve
detailed supporting evidence on a user-specified candi-
date gene from the published microarray and proteomic
studies in HCC. The development of Liverome was
initiated to compare our own gene signatures derived
from microarray experiments done on a large HCC
cohort in Korea (through “The 21C Frontier Functional
Human Genome Project of Korea”) with publicly
reported gene signatures. We found Liverome database
useful for prioritizing the genes present in our own sig-
natures for further in-depth studies. In the future, we
will continuously expand Liverome’s signature collection
once a year.
Availability and requirements
The database is available at http://liverome.kobic.re.kr
without login requirement. All contents in Liverome are
freely available for download and on-site use without
restriction.
Additional material
Additional file 1: Supplementary Tables This document contains all
supplementary tables (Tables S1 through S4).
Additional file 2: Supplementary Figures This document contains all
supplementary figures (Figures S1 through S6).
Additional file 3: Supplementary Methods This document contains
methods for co-occurrence network construction and module
identification.
Additional file 4: Supplementary Excel File This Excel file contains the
list of modules in the co-expression network and their enriched
pathways.
Figure 5 Co-occurrence network of genes in Liverome. Shown here is a matrix representation of the co-occurrence network, where genes
are represented on rows and columns in the same order. Elements in the matrix are color coded according to the similarity between
corresponding pairs of genes. Genes that are grouped into modules are indicated by the color bars and by the associated clustering trees.
Blocks along the diagonal indicate that the genes in the same module are more interconnected than those between modules. Details on the
plot can be found in the documentation of the WGCNA package. The enriched biological pathways for selected modules are also shown. The
modules are numbered as indicated in Additional File 4.
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